Strategic management of innovation risk in the biopharmaceutical industry: a UK perspective

International Journal of Healthcare Technology and Management

Volumn 1, Issue 1-2, 1999, Pages 62-76

  Chandrasekar, C R ^a   Helliar, C V ^a   Lonie, A A ^a   Nixon, W A ^a   Power, D M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Biopharmaceutical industry; innovation risk; strategic management

Indexed keywords

EID: 0010864326     PISSN: 13682156     EISSN: 17415144     Source Type: Journal    
DOI: 10.1504/ijhtm.1999.001052     Document Type: Article

References (36)

1. Sykes, R. (1994) ‘Editorial. Innovation in the pharmaceutical industry’, British Medical Journal, Vol. 309, pp.422–423.
2. House of Lords Select Committee on Science and Technology (1991) ‘Innovation in the manufacturing industry’, Third Report, Definitions of R&D, HMSO, London.
3. ABPI (1996) ABPI Annual Review, The Association of the British Pharmaceutical Industry, London.
4. OECD (1994) Science and Technology Policy: Review and Outlook, OECD, Paris.
5. Anderson, J. and Fears, R. (1996) ‘Sustaining the strength of the UK in healthcare and life sciences R&D: competition, cooperation and cultural change’, A report on the Third SmithKline Beecham R&D Policy Symposium, London 24–25 October, ScienceBridge, London.
6. Green, D. (1997) ‘Britain – survey of pharmaceuticals’, Financial Times, 24 April (supplement), p.2 and p.5.
7. Ernst and Young (1995) ‘European biotech: gathering momentum’, The Second Annual Ernst & Young Report on the European Biotechnology Industry.
8. Whittaker, E. and Bower, D.J. (1994) ‘A shift to external alliances for product development in the pharmaceutical industry’, R&D Management, Vol. 24, No. 3, pp.249–260.
9. Sykes, R. (1995) ‘Glaxo Wellcome’, Financial Times, 5 December.
10. Burrill, S. (1996) ‘Burrill and Caves’, Financial Times, 25 March.
11. Davidson, S. (1997) ‘Why venture capital will fund industrial biotechnologies soon’, Nature Biotechnology Supplement, June, p.20.
12. Biggadike (34) noted that it took on average eight years for an innovative product of a major US corporation to break even and twelve before the profitability of such a product reached the average level of the company as a whole. Analyses of the US pharmaceutical company, Merck & Co., by Lewent and Kearney (35) and Nichols (36) make a similar point about the long lags which often exist between the inception and payoff of innovative products. Pharmaceutical companies anticipate such lags in the strategic management of their portfolios of products and consequently do not reject innovations on the basis of the traditional discounted cash flow (DCF) project appraisal technique, which discounts distant uncertain payoffs very heavily because the evaluation ignores the strategic benefits of the investment and concentrates on the analysis of single product cash flows as if the firm had no other products.
13. Walker, M. and Southworth, A. (1996) ‘Biotechnology: can the UK sustain its competitive advantage?’, Management and Accounting, November, pp.22–26.
14. Anderson, J. and Fears, R. (1995) ‘Valuing and evaluating: assessment of the value of R&D in creating national and corporate prosperity’, A report on the Second SmithKline Beecham R&D Policy Symposium, London 31 October- 2 November, Cross & Associates, London.
15. Vagelos, P.R. (1991) ‘Are prescription drug prices too high?’ Science, Vol. 252, pp.1080–1084.
16. Gittins, J. (1997) ‘Why crash pharmaceutical research?’, R&D Management, Vol. 27, No. 1, pp.79–85.
17. Halliday, R.G., Drasdo, A.L., Lumley, C.E. and Walker, S.R. (1997) ‘The allocation of resources for R&D in the world’s leading pharmaceutical companies’, R&D Management, Vol. 27, No. 1, pp.63–77.
18. Lonie, A.A., Nixon, B. and Collison, D. (1993) ‘Internal and external financial constraints on investment in innovation and technology’, in P. Swan (ed.,), New Technologies and the Firm, Routledge, pp.265–291.
19. Berry, M.M. and Taggart, J.H. (1994) ‘Managing technology and innovation: a review’ R&D Management, Vol. 24, No. 4, pp.341–353
20. Pavitt, K. (1990) ‘What we know about the strategic management of technology’, California Management Review, Spring, pp.17–26.
21. Tushman, S.L. and Anderson, P. (1997) Managing Srategic Innovation and Change, Oxford University Press, Oxford.
22. Margrabe, W. (1978) ‘The value of an option to exchange one asset for another’, The Journal of Finance, Vol. 33, No. 2, pp.177–186.
23. Kester, W.C. (1984) ‘Today’s options for tomorrow’s growth’, Harvard Business Review, March-April, pp.153–160.
24. Dixit, A.K. and Pindyck, R.S. (1994) Investment under Uncertainty, Princeton University Press, Princeton, NJ.
25. Sick, G. (1995) ‘Real options’, in R.A. Jarrow et al., (eds.) Handbooks in OR & MS, Vol. 9, Financial Management, North- Holland BV, Amsterdam, pp.631–691.
26. Ross, S.A. (1995) ‘Uses, abuses, and alternatives to the net-present-value rule’, Financial Management, Vol. 24, No. 3, pp.96–102.
27. Schwab, B. and Schwab, H. (1997) ‘Better risk management: a key to improved performance’, Journal of General Management, Vol. 22, No. 4, Summer, pp.65–76.
28. Busby, J.S. and Pitts, C.G.C. (1997) ‘Real options in practice: an exploratory survey of how finance officers deal with flexibility in capital appraisal’, Management Accounting Research, Vol. 8, pp.169–186.
29. Howell, S.D. and Jagle, A.J. (1997) ‘Laboratory evidence on how managers intuitively value real growth options’, Manchester Business School Working Paper, Manchester.
30. Porter, M.E. (1980) Competitive Strategy, NY Free Press, New York.
31. She argued that developing new products “is a risky business because pharmaceuticals have a long development cycle and require a lot of investment” before they even begin to generate sales; “some products,” she added, “can spend 13 years in development and never hit the market.”
32. Therefore they selected a mix of products with varying risks of commercial success and aimed at a variety of markets; they did not “put all their eggs in the one basket”.
33. This procedure also limited the downside risk faced by the firm since it reduced the amount of funds which the case study company had to invest in a new product.
34. Biggadike, R. (1979) ‘The risky business of diversification’, Harvard Business Review, May-June, pp.103–111.
35. Lewent, J.C. and Kearney, A.J. (1990) ‘Identifying, measuring and hedging currency risk at Merck’, Journal of Applied Corporate Finance, Vol. 2, No. 4, pp.19–27.
36. Nichols, N.A. (1994) ‘Scientific management at Merck: an interview with CFO Judy Lewent’, Harvard Business Review, Jan-Feb, pp.89–99.